WebPatients were randomized (1:1) to pembrolizumab 200 mg or placebo in combination with carboplatin, and investigator’s choice of either paclitaxel every 3 weeks or nab … WebMar 31, 2024 · The first-line chemotherapy regimens were paclitaxel + carboplatin, pemetrexed + carboplatin, gemcitabine + carboplatin, and other. ... causing about 25% of all cancer-related deaths worldwide. 1 Nearly 85% of lung cancers diagnosed are non-small-cell lung cancer (NSCLC), 2 for which interstitial lung disease (ILD) is an …
Paclitaxel and carboplatin in inoperable non-small-cell lung …
WebSep 21, 2016 · In the weekly arm, paclitaxel was administered at 75 mg/m 2 /wk on a continuous basis for 12 weeks, whereas carboplatin (AUC = 6 mg/mL · min) was administered on day 1 every 3 weeks, and this was compared with the regimen of standard carboplatin and paclitaxel every 3 weeks as in our study. WebWeekly carboplatin in combination with weekly paclitaxel results in good response rates and acceptable toxicity in patients with advanced and metastatic NSCLC including patients with poor risk features (brain metastases, older age, and impaired PS). Nonetheless, selecting the right patient for a pla … druk cuk
Carboplatin and weekly paclitaxel in non-small cell lung cancer ...
Web1 day ago · Roundtable Discussion: Bodor Reviews Benefits, Challenges of Immunotherapy for Squamous NSCLC. During a Targeted Oncology™ Case-Based Roundtable™ event, J. Nicholas Bodor, MD, PhD, MPH, discussed the CheckMate 9LA regimen of nivolumab and ipilimumab plus chemotherapy for patients with advanced squamous non–small cell … WebMar 31, 2024 · The first-line chemotherapy regimens were paclitaxel + carboplatin, pemetrexed + carboplatin, gemcitabine + carboplatin, and other. ... causing about 25% … WebOct 30, 2024 · Affiliations 1 Department of Thoracic Oncology/Internal Medicine, Thoraxklinik im Universitätsklinikum Heidelberg.; 2 Translational Lung Research Center … druk dn-1